Risk categories in which the patients were stratified
| 1. NCCN-FR |
| Inv(16) |
| t(8;21) |
| t(16;16) |
| RUNX1/RUNX1T1 without c-Kit mutations |
| CBFβ/MYH11 without c-Kit mutations |
| NPM1 mutation without FLT3 mutations |
| 2. NCCN-IR postconsolidation MRD negative |
| Normal karyotype |
| +8 only |
| t(9;11) only |
| Other karyotypic abnormalities not listed as FR or PR |
| RUNX1/RUNX1T1 with c-Kit mutation |
| CBFb/MYH11 with c-Kit mutation |
| No NPM1 mutations |
| No FLT3-ITD mutations |
| 3. NCCN-IR postconsolidation MRD positive |
| As in 2 but with measurable MRD after the consolidation course |
| 4. NCCN-PR |
| Complex karyotype (≥3 abnormalities) |
| −5/5q- |
| −7/7q- |
| Abnormalities of 11q23, excluding t(9;11) |
| inv(3) |
| t(3;3) |
| t(6;9) |
| FLT3-ITD mutations |
| 5. NCCN-IR-no LAIP |
| Patients belonging to the IR category in whom no leukemia associated |
| Immunophenotype (LAIP) was identified, at diagnosis |
| 1. NCCN-FR |
| Inv(16) |
| t(8;21) |
| t(16;16) |
| RUNX1/RUNX1T1 without c-Kit mutations |
| CBFβ/MYH11 without c-Kit mutations |
| NPM1 mutation without FLT3 mutations |
| 2. NCCN-IR postconsolidation MRD negative |
| Normal karyotype |
| +8 only |
| t(9;11) only |
| Other karyotypic abnormalities not listed as FR or PR |
| RUNX1/RUNX1T1 with c-Kit mutation |
| CBFb/MYH11 with c-Kit mutation |
| No NPM1 mutations |
| No FLT3-ITD mutations |
| 3. NCCN-IR postconsolidation MRD positive |
| As in 2 but with measurable MRD after the consolidation course |
| 4. NCCN-PR |
| Complex karyotype (≥3 abnormalities) |
| −5/5q- |
| −7/7q- |
| Abnormalities of 11q23, excluding t(9;11) |
| inv(3) |
| t(3;3) |
| t(6;9) |
| FLT3-ITD mutations |
| 5. NCCN-IR-no LAIP |
| Patients belonging to the IR category in whom no leukemia associated |
| Immunophenotype (LAIP) was identified, at diagnosis |